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Abstract
Members of the miR-200 family are critical gatekeepers of the
epithelial state, restraining expression of pro-mesenchymal genes
that drive epithelial–mesenchymal transition (EMT) and contribute
to metastatic cancer progression. Here, we show that miR-200c
and another epithelial-enriched miRNA, miR-375, exert widespread
control of alternative splicing in cancer cells by suppressing the
RNA-binding protein Quaking (QKI). During EMT, QKI-5 directly
binds to and regulates hundreds of alternative splicing targets and
exerts pleiotropic effects, such as increasing cell migration and
invasion and restraining tumour growth, without appreciably
affecting mRNA levels. QKI-5 is both necessary and sufficient to
direct EMT-associated alternative splicing changes, and this splic-
ing signature is broadly conserved across many epithelial-derived
cancer types. Importantly, several actin cytoskeleton-associated
genes are directly targeted by both QKI and miR-200c, revealing
coordinated control of alternative splicing and mRNA abundance
during EMT. These findings demonstrate the existence of a miR-
200/miR-375/QKI axis that impacts cancer-associated epithelial cell
plasticity through widespread control of alternative splicing.
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Introduction
The ability of cells to reversibly transition between epithelial and
mesenchymal states (epithelial-to-mesenchymal transition, EMT) is
exploited by tumours to drive malignant progression. EMT is
governed by networks of transcriptional and post-transcriptional
mechanisms. A reciprocal feedback loop between the miR-200
family and ZEB1/2 transcription factors plays a central role in
epithelial cell plasticity (Bracken et al, 2008; Burk et al, 2008;
Gregory et al, 2011), and by virtue of its potency functions widely
in controlling cell invasiveness, stemness and tumour metastasis
(Gibbons et al, 2009; Wellner et al, 2009; Brabletz & Brabletz,
2010). However, in addition to ZEB1/2, miR-200 can regulate many
other target genes that contribute to these functions (Bracken et al,
2014, 2016; Perdigao-Henriques et al, 2016), although for most of
these interactions the implications for cancer progression are not
well understood.
Alternative splicing is an additional layer of post-transcriptional
control that exhibits widespread changes during EMT and has
causal effects on epithelial cell function (Warzecha et al, 2010;
Shapiro et al, 2011). The epithelial spliced regulatory proteins
(ESRP1 and ESRP2) play prominent roles in maintaining epithelial
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alternative splicing patterns, and loss of ESRP expression in the
mesenchymal state results in alterations to the these patterns
(Warzecha et al, 2009; Brown et al, 2011). Several other RNA-
binding proteins including RBFOX2, MBNL1/2, RBM47 and Quaking
(QKI) have also been reported to directly influence mesenchymal
associated alternative splicing (Shapiro et al, 2011; Venables et al,
2013a,b; Braeutigam et al, 2014; Yang et al, 2016); however, the
direct contribution of these factors to alternative splicing and the
mechanisms controlling their expression during EMT remain largely
uncharacterised.
We find here that miR-200 exerts a widespread influence on
alternative splicing during EMT, through its strong regulation of
QKI. QKI is a member of the STAR family of RBPs and has been
reported to have diverse functions in mRNA stability (Larocque
et al, 2005; Zhao et al, 2006) and translation (Saccomanno et al,
1999; de Bruin et al, 2016b), miRNA processing (Wang et al, 2013,
2017) and alternative splicing (Hall et al, 2013; van der Veer et al,
2013; Zong et al, 2014; de Bruin et al, 2016a; Darbelli et al, 2017;
Fagg et al, 2017; Hayakawa-Yano et al, 2017). We have recently
shown that QKI can promote circular RNA formation during EMT
(Conn et al, 2015), although the functional consequences of QKI in
EMT remain unclear. While seeking to identify the miR-200 targets
most biologically relevant to cancer progression, we surprisingly
found that QKI is one of the most consistent clinical correlates of
miR-200 activity. QKI is strongly regulated by miR-200 and miR-375,
directly binds to and mediates hundreds of alternative splicing
events, and regulates multiple facets of mesenchymal cell plasticity
without significantly perturbing gene expression. Our findings impli-
cate alternative splicing as an important regulator of cell plasticity
and broaden the network of post-transcriptional changes orches-
trated by miR-200. Given the important roles of miR-200, miR-375
and QKI in cell differentiation, we propose this pathway may define
transcript selection in a broad range of biological contexts.
Results
QKI is inversely correlated with miR-200c in cancer
To identify miR-200c targets that may be especially relevant to
cancer progression, we created a ranking method that merges
microRNA–mRNA correlations from cancer and cell line data sets,
EMT data sets and Ago-HITS-CLIP data (Figs 1A and EV1A). The
first and third highest ranked genes were ZEB1 and ZEB2, but
surprisingly, the second highest ranked gene was the RNA-binding
protein QKI (Fig 1B), which has not been described to be a target of
miR-200, but was recently shown to regulate circRNA production in
human mammary epithelial cells (HMLE) that have undergone EMT
(Conn et al, 2015). To assess whether the negative correlation holds
at the protein level, we measured QKI protein in a panel of breast
cancer cell lines, which showed an even stronger negative correla-
tion with miR-200c (Fig 1C).
Examination of QKI expression in breast cancer cohorts showed
it was upregulated in basal-like and claudin-low subtypes, which
display enhanced EMT-like features, and is indicative of poor distant
metastasis-free survival (Figs 1D and EV1B and C). Moreover, in
prostate cancer, QKI was elevated with increasing Gleason grade, in
recurrent prostate cancers, and in metastases in several cohorts
(Figs 1E and F, and EV1D). These data are consistent with QKI-
mediating properties that promote tumour progression, such as cell
migration and invasion, which are potently repressed by the miR-
200 family (Bracken et al, 2014).
To assess whether the miR-200c–QKI inverse relationship is
observed more broadly across other cancers, we examined the pan
TCGA panel, which demonstrated QKI displays a strong negative
recurrence score with miR-200c across the 10 represented tumour
types (Fig 1G). Furthermore, when we examined all miRNAs for an
inverse relationship with QKI across the 10 cancer types, we found
the miRNAs with strongest negative recurrence with QKI are the
members of the miR-200 family, along with miR-7 and miR-375
(Fig 1H). Together, these data demonstrate a consistent relationship
between miR-200c and QKI in diverse experimental and clinical data
sets, suggesting miR-200c may directly target QKI, with conse-
quences for cancer progression.
QKI-5 is directly targeted by miR-200c and miR-375
The QKI locus encodes three major isoforms, QKI-5, QKI-6, and
QKI-7, named as such because the mRNAs were estimated to be 5, 6
and 7 kb, respectively (Ebersole et al, 1996). These isoforms differ
in their carboxyl-termini and their 30UTRs, but the 30UTR
polyadenylation sites were poorly characterised, with their RefSeq
entries being discordant with the published sizes of the mRNAs.
Consequently, to enable assessment of whether the negative
▸Figure 1. Quaking is a direct target and inversely correlates with miR-200c and miR-375 in cancer.A Flow chart of pipeline used to discover miR-200c targets relevant to cancer.
B Comparison of the top 20 miR-200c targets in listed experimental and clinical data sets ranked in order of consistency. An “X” in experimental data sets indicates
evidence of miR-200 targeting. For clinical data sets (Liu et al, 2010; Taylor et al, 2010; Enerly et al, 2011), Pearson correlation coefficients between miR-200c and
target genes are shown with significant values indicated in red.
C Relative expression of QKI, E-cadherin and miRNAs in a human breast cancer panel of epithelial and mesenchymal cell lines.
D–F Relative expression of QKI in tumour subtypes of the University of North Carolina 779 breast cancer set (Harrell et al, 2012), Gleason grades of the TCGA prostate
cancers, and primary (P) versus metastases (M) from prostate cancer data sets listed by the first author (Lapointe et al, 2004; Varambally et al, 2005; Chandran
et al, 2007; Tamura et al, 2007; Taylor et al, 2010; Grasso et al, 2012) shown as box-and-whisker plots. Box limits represent the 25th–75th percentiles with a median
central line. For (D) and (E), whiskers extend to the minimum and maximum values with all data points shown. For (F), whiskers represent the 10th–90th
percentiles. Expression differences were assessed by two-sample equal variance t-tests ***P < 0.001, **P < 0.01, *P < 0.05.
G, H Recurrence scores of the top 20 target genes from (B), and the top 20miRNAs that inversely correlate with QKI in the panTCGA cancer data set as calculated using
CancerMiner (Jacobsen et al, 2013). Asterisks refer to minor form mature miRNA derived from the pre-miRNA (in this case miR-7-1-3p, miR-200b-5p and
miR-200c-5p).
Source data are available online for this figure.
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ZEB1 X X X X -0.34 -0.45 -0.46 -0.50 -0.57
QKI X X X X -0.42 -0.29 -0.31 -0.32 -0.67
ZEB2 X X X -0.58 -0.41 -0.39 -0.45 -0.75
LHFP X X X X -0.53 -0.45 -0.23 -0.37 -0.39
WIPF1 X X -0.38 -0.24 -0.45 -0.42 -0.67
SEC23A X X X X -0.40 -0.32 -0.24 -0.53 -0.27
TIMP2 X X -0.37 -0.41 -0.45 -0.53 -0.40
MSN X X X -0.35 -0.10 -0.46 -0.59 -0.75
AP1S2 X X X -0.50 -0.21 -0.13 -0.35 -0.61
CCDC82 X X -0.45 -0.19 -0.36 -0.41 -0.43
JAZF1 X X -0.35 -0.41 -0.55 -0.53 -0.41
CRTAP X X X -0.36 -0.45 -0.29 -0.51 -0.50
RUSC2 X X X -0.21 -0.23 -0.39 -0.51 -0.47
DLC1 X X -0.45 -0.39 -0.36 -0.34 -0.46
MYLK X X -0.34 -0.29 -0.46 -0.51 -0.47
ETS1 X X -0.37 -0.28 -0.31 -0.34 -0.57
HEG1 X X -0.46 -0.43 -0.38 -0.44 -0.54
FSTL1 X X X -0.46 -0.43 -0.02 -0.25 -0.41
ZCCHC24 X X -0.52 -0.48 -0.39 -0.48 -0.47
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correlation between miR-200c and QKI was due to direct regulation
of QKI by miR-200c, we first characterised the 30UTRs of each major
isoform, using short- and long-read RNA-seq, and by RT–PCR using
specific reverse transcription primers tiled across the annotated
30UTRs (Fig EV2). This analysis showed that QKI-6 and QKI-7 have
a similar 30UTR, differentiated only by an additional segment at the
beginning of the QKI-7 30UTR, whereas QKI-5 has a completely
distinct 30UTR of 2.3 kb in length. Isoform-specific qRT–PCR
showed that QKI-5 mRNA is expressed at a much higher level than
QKI-6 and QKI-7 in breast cancer and TGF-b-treated mammary
epithelial cells (Fig EV3A–D), and immunoblotting confirmed QKI-5
protein is much more abundant than the other isoforms (Fig 2A).
The QKI-5 30UTR has two predicted 8-mer binding sites for miR-
200b/c that correspond to miR-200b peaks in our previous HITS-
CLIP analysis of miR-200 binding sites (Bracken et al, 2014). In
addition, we noticed the QKI-5 30UTR also has multiple potential
7-mer sites for miR-375, which the association analysis had indi-
cated is negatively correlated with QKI in multiple cancer types
(Figs 1H and EV1E).
To verify that miR-200c and miR-375 regulate QKI levels, we
examined the effect of overexpression of these miRNAs on QKI
mRNA and protein, and on luciferase reporters bearing the QKI-5
30UTR (Fig 2). Overexpression of miR-200c and miR-375 each
reduced the level of QKI-5 and QKI-6 mRNAs and decreased all three
QKI isoform proteins (Fig 2A). In contrast, miR-141, which differs
from miR-200c by one nucleotide in its seed region, did not reduce
QKI levels. Since QKI-5 is the major isoform in the breast cancer
cells, we used the QKI-5 30UTR to test for direct miRNA targeting.
Both miR-200c and miR-375, but not miR-141, strongly repressed
the full-length QKI-5 30UTR reporter, replicating their effects on QKI
expression (Fig 2B). Analysing the QKI-5 30UTR proximal and distal
regions in isolation revealed direct targeting of the distal region by
the conserved miR-200c sites and the proximal region by two miR-
375 sites, with repression of each abrogated by mutation of these
sites (Fig 2B). These data demonstrate that miR-200c and miR-375
directly target the major QKI isoform by binding its 30UTR and also
directly or indirectly reduce the levels of the QKI-6 and QKI-7
isoforms.
QKI-5 is dynamically regulated during EMT
Having confirmed QKI is regulated by miR-200 and miR-375, we
assessed whether the expression of QKI is physiologically regulated
during EMT, and in a reciprocal manner to these miRNAs. Consis-
tent with its reciprocal relationship with miR-200 and miR-375 in
cancer, QKI expression increased during TGF-b-induced EMT of
human breast and canine kidney epithelial cells (Fig 3A) and during
ZEB1-induced EMT of LNCaP human prostate cancer cells (Fig 3B).
In each of these systems, QKI-5 protein was more responsive to the
changes in miR-200c and miR-375 than was QKI-5 mRNA, consis-
tent with the stronger effect on protein seen in Fig 2A. Examining
this further, we observed that short-term inhibition of miR-200c or
miR-375 increased QKI-5 protein in a dose-dependent manner with
little effect on QKI-5 mRNA, suggesting these miRNAs especially
affect translation of the QKI-5 mRNA (Fig 3C). Together, these find-
ings show QKI-5 is robustly and dynamically regulated as cells tran-
sition between epithelial and mesenchymal states in a manner
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Figure 2. Quaking is directly targeted and repressed by miR-200c and
miR-375.
A Real-time PCR and Western blot of total QKI (panQKI) and individual QKI
isoforms following transfection of MDA-MB-231 and TGF-b-treated
mammary epithelial cells (mesHMLE) with miRNA precursors (Pre-miRs).
B Schematic of the luciferase QKI-5 30UTR reporter constructs indicating the
miR-200c and miR-375 binding sites (top) and reporter assays of indicated
QKI-5 30UTR constructs with co-transfection of Pre-miRs into MDA-MB-231
cells (bottom). Constructs with mutations in the miR-375 or miR-200c sites
are suffixed with “m”. Data are represented as mean  SD (n = 3).
Significance was measured by two-tailed unpaired t-tests. *P < 0.05 and
***P < 0.001.
Source data are available online for this figure.
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QKI-5 regulates epithelial cell plasticity and exerts pleiotropic
effects on cell migration, invasion and tumour growth
Several studies have indicated QKI plays tumour suppressive roles
in cancer (Chen et al, 2012; Zong et al, 2014; Bandopadhayay et al,
2016), but its ability to regulate EMT remains unclear. To establish
whether the regulation of QKI-5 during EMT has consequences for
EMT-related cell properties, we examined the effect of modulating
QKI-5 on cell shape, and on migratory and invasive ability.







































































































































































Figure 3. Quaking is dynamically regulated during EMT/MET and is translationally repressed by miR-200c and miR-375.
A Epithelial cell lines were treated with TGF-b for the indicated time periods. Changes in expression of proteins were measured by Western blot, miR-200c by qPCR,
with relative changes in QKI-5 mRNA and protein represented in graphs below.
B LNCaP cells with inducible ZEB1 were treated with doxycycline for 6 days followed by its withdrawal for 10d. Changes in expression of proteins were measured by
Western blot, miR-200c and miR-375 by qPCR, with relative changes in QKI-5 mRNA and protein represented in graphs below.
C MCF-7 cells were transfected with increasing doses (20, 50 or 100 nM) of control (neg), miR-200c or miR-375 LNA inhibitors (anti-miR) for 3 days. Western blot of
QKI-5 protein levels is shown and quantitated, along with QKI-5 mRNA by qPCR. White bars represent change in expression relative to the negative control at 20 nM.
Source data are available online for this figure.
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spindle-shaped to a cuboidal morphology, with reduced length-to-
width ratio and increased cell area, while QKI-5 overexpression had
the opposite effect, promoting an even more spindle-shaped
morphology with increased length-to-width ratio (Fig 4A and B).
Moreover, reduction of QKI-5 phenocopied overexpression of miR-
200c in increasing focal adhesions, most clearly demonstrated in
SH-EP neuroblastoma cells where changes in number and length
were readily quantifiable (Fig 4A and C). However, QKI-5 knock-
down was not sufficient to drive a full return to epithelial form, as
evidenced by the lack of change in levels of multiple epithelial and
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mesenchymal markers (Fig EV3E) and the failure to form E-
cadherin and b-catenin-containing cell–cell junctions, which is in
contrast to the effect of miR-200 (Fig 4A).
To examine the effect of QKI-5 on cell migration and invasion, we
knocked down and overexpressed QKI-5 in MDA-MB-231 and
mesHMLE cells and monitored the effect by transwell assay and by
single-cell tracking. Mesenchymal cell migration and invasion were
strongly reduced by QKI-5 knockdown, roughly in proportion to the
effectiveness of the knockdown, while cell invasiveness was increased
by QKI-5 overexpression (Fig 4D and E). SH-EP cell invasion was also
reduced by QKI-5 knockdown (Fig EV3F), consistent with the stabilis-
ing effect seen on focal adhesions. Together, these data demonstrate
QKI-5 stimulates changes in cell migration, invasion, focal adhesions
and morphology, but unlike miR-200c, knockdown of QKI-5 does so
without reverting cells to a fully epithelial phenotype.
As QKI has previously been implicated to have tumour suppres-
sive roles, we tested its ability to regulate colony formation, a
measure of anchorage independent cell growth. We found that
mesHMLE cells robustly formed colonies in soft agar and that QKI
knockdown enhanced, while QKI overexpression inhibited, this abil-
ity (Fig 4F). Therefore, in addition to enhancing cell migration and
invasion (Fig 4D and E), QKI appears to concurrently reduce tumour
formation capacity in mesHMLE cells. We further tested this in the
tumorigenic MDA-MB-231 LM2 subline which also showed that
while QKI-5 kd decreases cell migration and invasion, it significantly
increased tumour growth (Fig 4G and H). These data indicate that
QKI can exert multiple influences in cancer, potentially through
regulating different target genes.
QKI-5 has little effect on gene transcription during EMT, but has
broad effects on alternative splicing
QKI plays diverse functions in RNA metabolism and therefore may
conceivably regulate epithelial cell plasticity through several
mechanisms. To assess the relevance of QKI-5 as a miR-200 target
during EMT, we performed transcriptomic analysis of cells before
and after initiation of EMT with TGF-b, and also assessed the tran-
scriptomes of the resulting mesenchymal cells in response to miR-
200c overexpression or to QKI-5 knockdown. RNA sequencing was
performed on multiple replicates and at high depth to provide reli-
able quantitation of expression and alternative splicing (Table EV1).
The expression of many genes was changed during the EMT, and
many of these changes were reversed by restoration of miR-200c;
however, most of the expression changes were not restored by
knockdown of QKI-5 (Fig 5A). TGF-b and miR-200c had largely
opposing effects on gene expression, significantly altering 2,677 and
2,656 genes, respectively (fold change > 2, q-value < 0.05), includ-
ing archetypal epithelial (e.g. E-cadherin, occludin and desmo-
plakin) and mesenchymal (e.g. fibronectin, ZEB1 and ZEB2) genes
(Figs 5A and C, and EV4A and Table EV2). In contrast, QKI-5 knock-
down altered a much smaller subset of genes (787), and mostly to a
lesser extent than either TGF-b or miR-200c, and did not cause
significant changes in the hallmark EMT genes (Figs 5A and C, and
EV4A and Table EV2). Furthermore, there was little consistency in
the genes that were affected by QKI-5 knockdown in mesHMLE cells
compared to knockdown in MDA-MB-231 cells (Fig EV4B and
Table EV3). This was in contrast to miR-200c overexpression, which
elicited similar changes in gene expression in both cell lines
(Fig EV4C). Thus, the majority of transcriptomic alterations elicited
by loss of miR-200 during EMT are not a result of QKI-5 upregulation.
In contrast, alterations to the relative levels of alternative splice
isoforms that occurred during EMT were frequently counteracted by
both overexpression of miR-200c and knockdown of QKI (Fig 5B).
These commonly regulated alternative splicing events were predom-
inantly comprised of exon skipping, exon inclusion and/or mutually
exclusive exon usage (Fig 5D and Table EV4). Indeed, of the 1,138
alterations to skipped or included exon events that occurred in
response to TGF-b-mediated EMT, 356 (or 31%) were regulated by
Figure 4. QKI-5 regulates epithelial cell plasticity and associated phenotypic properties.
A Phase contrast and fluorescent microscopy of F-actin, paxillin, E-cadherin and b-catenin in MDA-MB-231 cells transfected with control (neg), QKI-5 siRNA or miR-
200c for 3 days. QKI-5-overexpressing (OE) MDA-MB-231 cells are also included in this panel. Cells are counterstained with DAPI (blue). Scale bars represent 50 lm.
B Cell shape specified by length-to-width ratio and cell area were measured in 60 F-actin-stained cells from (A). Data are displayed as box-and-whisker plots. Box limits
represent the 25th–75th percentiles with a median central line. Whiskers represent the 10th–90th percentiles. Points below and above the whiskers are shown.
Significance between indicated groups was measured by a two-tailed Mann–Whitney test.
C Paxillin staining of SH-EP cells transfected with control (neg), QKI-5 siRNA or miR-200c for 3 days. Focal adhesion lengths (min 500 counted) were calculated using at
least 20 cells per treatment. Exact cell numbers and focal adhesion measured for each group are as follows: neg si (35, 698), QKI-5 #1 si (23, 766), QKI-5 #2 (24, 553) and
miR-200c (31, 1,067). For focal adhesion length, data are displayed as a box-and-whisker plot and significance between indicated groups was measured by a two-tailed
Mann–Whitney test. Box limits represent the 25th to 75th percentiles with a median central line. Whiskers represent the 10th–90th percentiles. Points below and above
the whiskers are shown. Focal adhesion numbers were counted in individual discrete cells and graphed as focal adhesion numbers per cell (mean  SD). Exact cell
numbers for each group are as follows: neg si (22), QKI-5 #1 si (23), QKI-5 #2 (21) and miR-200c (24). Western blot with changes in QKI-5 levels is shown below.
D Migration and invasion assays following shRNA-mediated knockdown (kd) or cDNA overexpression (OE) of QKI-5. Western blot with changes in QKI-5 levels is shown
below. mCherry-expressing cell lines are shown as a control. Experiments were performed using at least three biological replicates and shown as mean  SEM. Exact
numbers for each group for both migration and invasion are as follows: MDA-MB-231 Control (10), shQKI#2 (7), shQKI#5 (3), mCherry (18) and QKI-5 OE (18); and
mesHMLE Control (3), shQKI#2 (3), shQKI#5 (3), mCherry (6) and QKI-5 OE (3).
E Non-directional migration of MDA-MB-231 cells following QKI-5-specific siRNA kd. Cell tracking of 25 cells per group was measured for 24 h and is depicted in
windrose plots. Relative mean distance and velocity are shown as mean  SD. Western blot with changes in QKI-5 levels is shown below.
F Soft agar colony formation of mesHMLE cells with QKI kd or OE after 14 days (n = 9, mean  SEM). Representative pictures of colonies are shown.
G Migration and invasion assays of MDA-MB-231-LM2 cells following QKI kd (n = 3, mean  SEM).
H Growth of mammary tumours from MDA-MB-231-LM2 cells with QKI kd. Exact mouse numbers for each group are as follows: Cont (10), shQKI#2 (10) and shQKI#5
(9, one tumour did not grow). Data are graphed as mean  SEM, and significance was calculated by two-way ANOVA with Dunnett’s multiple comparisons test
performed at each time point.
Data information: Unless otherwise indicated, significance was measured by two-tailed unpaired t-tests. P-values for all tests are indicated as *P < 0.05, **P < 0.01 and
***P < 0.001.
Source data are available online for this figure.
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QKI-5 (Fig EV4D and Table EV5). These data indicate that the miR-
200/QKI-5 axis is a major regulator of alternative splicing during
EMT.
Modulation of QKI-5 level is necessary and sufficient to
alter splicing
To identify alternative splicing events in EMT that are directly regu-
lated by QKI-5, we performed HITS-CLIP analysis of nuclear QKI-5
in mesHMLE cells. This technique identified a large number of
potential QKI-5 binding sites across the transcriptome, predomi-
nantly within introns (Fig EV4E). Highlighting the robustness of the
data set, motif analysis revealed strong enrichment of the QKI target
motif, ACUAAC, and this sequence generally occurred near the
centre of the HITS-CLIP peak (Fig EV4F and G). To explore how
QKI-5 may function to promote skipping of some exons but inclu-
sion of others, we plotted the average QKI-5 HITS-CLIP peak heights
in the introns flanking the 597 exons whose exclusion or inclusion
was strongly regulated by QKI-5 (change in percentage spliced in
(DPSI) > 20%). This showed that exon skipping events were typi-
cally accompanied by QKI binding either within the skipped exon or
within 100 nt upstream of the skipped 30 splice site, whereas QKI-
mediated exon inclusion involved binding of QKI within the down-
stream intron (Fig 5E).
To validate these findings, we selected eleven splicing events that
were strongly regulated by QKI-5 and by miR-200c in the RNA-seq
data and were also predicted to involve direct binding by QKI-5
(Fig EV5A). For each of these candidates, we used RT–PCR to moni-
tor their splicing during EMT, and in mesHMLE and MDA-MB-231
cells treated with miRNAs or siRNAs targeting QKI (Figs 5F and
EV5B). We also examined the effects of miR-375, which targeted
QKI-5 to a similar extent as miR-200c. Overexpression of miR-200c
and miR-375 and knockdown of QKI each reversed the splicing pro-
files observed during EMT for all events tested (Figs 5F and EV5B).
By contrast, overexpression of miR-141, which does not target QKI-
5, had no effect on the splicing events. Furthermore, in a panel of
breast cancer cell lines, the reciprocal levels of both miR-200 and
miR-375 compared to QKI effectively demarcated the splicing profile
of these events (Fig 5G). Collectively, these data provide strong
evidence that a miR-200/miR-375/QKI axis broadly influences EMT-
associated splicing patterns.
To assess the extent to which QKI is necessary or sufficient to
regulate these splicing events, we treated HMLE cells with TGF-b
while simultaneously knocking down QKI-5 levels and examined
specific EMT-associated splicing events by PCR. Knockdown of QKI
robustly blocked the dynamic splicing changes that occured during
EMT, but did not alter changes in the EMT marker genes E-cadherin
and fibronectin, demonstrating that its upregulation was specifically
required for EMT-induced alternative splicing (Figs 6A and EV5C).
To determine whether miR-200c and miR-375 could induce splicing
alterations in the absence of an ability to target QKI-5, we over-
expressed a non-targetable form of QKI-5 (i.e. lacking its 30UTR) in
mesHMLE cells and in the presence or absence of ectopic delivery of
these miRNAs. QKI-5 overexpression augmented the degree of
mesenchymal splicing and completely abrogated the ability of
miR-200c and miR-375 to induce epithelial splicing patterns
(Fig 6B). As a further control, we showed that the QKI coding region
siRNA, but not the QKI-5 30UTR siRNA, repressed exogenous QKI-5
and reversed these splicing changes (Fig 5B). Together, these data
demonstrate that QKI-5 is the primary target by which these
miRNAs regulate EMT-associated alternative splicing events.
We next assessed the generalisability of these findings in other
EMT contexts. Firstly, we knocked down QKI in the LNCaP-iZEB1
model and found it was similarly essential for EMT-induced splicing
events but did not influence the level of archetypal EMT markers
(Fig 6C). To test whether QKI-5 induction is sufficient by itself to
drive EMT-associated splicing changes, we generated doxycycline-
inducible QKI-5-expressing prostate (LNCaP) and breast (MCF-7 and
HMLE) cell lines. In all cases, QKI-5 induction was associated with
dynamic changes in splicing of QKI-5 target genes, which were lost
upon withdrawal of doxycycline, and these changes occurred in the
absence of notable effects on cell morphology and EMT marker
expression (Figs 6D and E, and EV5D). Remarkably, QKI-5-regu-
lated splicing occurred without EMT inducers or the accompaniment
of other EMT effectors, indicating that QKI-5 levels alone are a
major determinant of splicing outcomes. Collectively, these data
demonstrate that miR-200c and miR-375 limit mesenchymal splicing
by repressing a single target, QKI-5, which is sufficient to direct an
EMT-associated alternative splicing programme.
De novo identification of QKI-regulated alternative splicing
reveals its widespread activity in cancers
To assess the relevance of QKI-mediated alternative splicing during
EMT to human cancers, we initially evaluated the relationship
between QKI expression and specific splicing events in TCGA breast
◀ Figure 5. QKI-5 directly binds to and controls alternative splicing of hundreds of EMT-associated splice events.A Heat map depicting differential expression of individual samples from the HMLE, mesHMLE, mesHMLE + QKI-5 kd and mesHMLE + miR-200c groups. Genes that
were detectably expressed (FPKM > 1) and whose change was at least twofold and statistically significant during EMT were included.
B Heat map depicting relative changes in skipped and included exon events of individual samples from the HMLE, mesHMLE, mesHMLE + QKI-5 kd and
mesHMLE + miR-200c groups. Events that are detected in all samples were utilised.
C Heat map depicting differential expression of hallmark epithelial and mesenchymal genes in the HMLE, mesHMLE, mesHMLE + QKI-5 kd and mesHMLE + miR-
200c groups.
D Tabulation of alternatively spliced events altered during EMT (HMLE to mesHMLE) and with QKI-5 kd or miR-200c overexpression in mesHMLE cells.
E QKI-CLIP map showing regional binding of QKI-5 in the flanking introns of skipped and included exon events regulated by QKI-5 knockdown with change in PSI
> 20%, FDR < 0.05. The significance of enrichment versus background (log10(P-value)) is graphed as lighter shade lines. Numbers of events where QKI-5
knockdown causes inclusion or exclusion are indicated. The background measurement is calculated using all exons that are spliced, but not differentially spliced, in
both mesHMLE and mesHMLE + QKI-5 kd.
F, G PCR of QKI-regulated splice events during EMT and (F) in mesHMLE cells transfected with miRNAs or QKI siRNAs, and (G) in epithelial (QKI-low) versus
mesenchymal (QKI-high) breast cancer cell lines. Exon annotations are denoted by the largest transcript. Major functions of the respective genes are indicated.
Source data are available online for this figure.
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cancer RNA-seq data. Supporting our in vitro findings, the splicing
of all genes verified to be directly regulated by QKI was highly corre-
lated with QKI levels (Fig 7A). We then constructed a metric to
quantify the global influence of QKI on alternative splicing in breast
cancer: More specifically, the PSI for every splice event in the tran-
scriptome was calculated for the 10% of samples with the highest
and lowest level of QKI. Plotting the difference in PSI (DPSI) versus
the statistical significance of the difference revealed several hundred
splice events that were highly dependent on the QKI level, including
all 20 of the genes that we had identified as the 20 most regulated
by QKI during EMT in vitro (Fig 7B and Table EV6). This demon-
strates that the alternative splice events most strongly associated
with QKI expression in breast cancers align closely with the
QKI-regulated events we had identified during EMT of cell lines, and
more broadly provides strong evidence that QKI is a prominent
driver of splicing changes in breast cancer.
To assess whether the influence of QKI on splicing in cancer
extends to carcinomas more generally, we repeated the analysis on
seven epithelial cancers for which there are at least 450 samples
present in the TCGA. To visualise the results, we performed unsu-
pervised clustering of the DPSI values (Fig 7C), which revealed a
cluster of QKI-responsive alternative splicing events that are
common across all cancer types, and a cluster of other QKI-respon-
sive events that are cancer-type-specific. The genes for which we
identified QKI binding sites proximal to the splice sites by QKI-HITS-














































































































































Figure 6. QKI is sufficient and necessary for EMT-associated splicing.
A–E Western blot of EMT markers and PCR of QKI-regulated alternative splicing events are shown following (A) TGF-b induction of EMT in HMLE cells transfected with
control or QKI-5 siRNAs, (B) transfection of mCherry- or QKI-5-overexpressing (OE) mesHMLE cells with miRNA or QKI siRNAs for 3 days, (C) doxycycline induction of
ZEB1 in LNCaP-iZEB1 cells transfected with control or QKI siRNA for 5 days, and (D, E) doxycycline induction of QKI-5 and subsequent withdrawal in LNCaP- and
MCF-7-iQKI-5 cells, with mCherry-expressing cell lines shown as an additional control.
Source data are available online for this figure.
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reinforcing the conclusion that QKI influences alternative splicing in
all of these cancers.
miR-200c coordinately regulates gene expression and alternative
splicing of actin cytoskeleton-associated targets
The studies described above demonstrated that QKI affects the
alternative splicing of numerous genes during EMT, for some
genes causing a relatively small change in the balance of splice
isoforms, but for some genes causing a more drastic change. We
also found that QKI strongly affects the morphology of cells as
well as their capacity to migrate and invade, which suggests that
genes involved in these processes may be alternatively spliced in
response to QKI. To assess this possibility, we performed gene
ontology (GO) analysis on the set of genes whose change in splic-
ing during EMT was reversed by knockdown of QKI
(Appendix Fig S1). The most enriched functional group was genes
involved in cell–cell adhesion followed by genes involved in
serine/threonine kinase activity, both of which are consistent with
changes that can affect cell motility. To apply a more stringent
criterion to the gene list, we restricted it to only include genes
that were confirmed to be direct QKI targets in the QKI-5 HITS-
CLIP analysis. This filtered gene list retained cell–cell adhesion
and serine/threonine kinase activity as highly enriched functional
groups, but the most significantly enriched group was genes
involved in regulation of the actin cytoskeleton (Fig 7D). We also
performed GO analysis on the set of genes whose alternative
splicing was consistently affected by QKI in different carcinomas
(Fig 7C), which confirmed that regulation of the actin cytoskele-
ton was the function most affected by QKI (Fig 7E).
Previous work from our laboratory has demonstrated that
miR-200 directly targets multiple genes involved in the actin
cytoskeleton regulatory network (Bracken et al, 2014). The obser-
vation that genes alternatively spliced by QKI during EMT and in
cancer are also frequently members of the actin cytoskeleton
network identifies a novel convergence of miR-200 function,
whereby it controls both alternative splicing of this network
(indirectly, via QKI) and gene expression (directly, via 30UTR
targeting). To identify genes regulated by both mechanisms, we
merged Ago-miR-200 HITS-CLIP targets (Bracken et al, 2014) with
QKI-5 HITS-CLIP targets, identifying 17 genes subject to both
direct miR-200 and direct QKI-5 regulation (Fig 7F). Remarkably,
10 of these genes exhibit highly conserved QKI-responsive splic-
ing changes across all cancer types (Fig 7F, shown in red). We
tested three actin-associated genes (MPRIP, NIN and MYOF) from
this list and found that miR-200c caused a dramatic switch in
their isoforms while simultaneously reducing their overall expres-
sion (Fig 7G). These genes form parts of actin-associated sub-
networks (Bracken et al, 2014), with many being direct miR-200
targets, QKI-5 targets or targets of both factors (Fig 7H). Collec-
tively, these data demonstrate the existence of a miR-200–QKI-5
regulatory pathway that coordinates widespread changes in gene
expression and alternative splicing of actin-associated gene
networks in cancer.
Discussion
It is well recognised that the miR-200 family are primary enforcers
of the epithelial phenotype through restraining expression of the
ZEB1/2 transcription factors (Burk et al, 2008; Gregory et al, 2008;
Korpal et al, 2008; Park et al, 2008). ZEB1 in particular invokes
transcriptional reprogramming that drives EMT, and associated
influences on tumour cell invasion, stemness and metastatic poten-
tial (Wellner et al, 2009; Chaffer et al, 2013; Lehmann et al, 2016;
Krebs et al, 2017). Despite the potency of this double-negative feed-
back loop leading to mutually exclusive expression of miR-200 and
ZEB1 (Gregory et al, 2008; Brabletz & Brabletz, 2010), miR-200
targets many other transcripts with potential relevance to cancer
progression (Bracken et al, 2014, 2016; Perdigao-Henriques et al,
2016). Here, we demonstrate that miR-200 constrains widespread
EMT-associated alternative splicing changes through translational
repression of a single RNA-binding protein QKI-5. QKI-5 is sufficient
to mediate plasticity between epithelial and mesenchymal states by
directing mesenchymal splicing alterations, especially within actin
cytoskeleton-associated genes, in the absence of major changes to
total mRNA levels. Thus, by targeting ZEB1 and QKI-5, miR-200
maintains epithelial cell identity by coordinately limiting transcrip-
tional and alternative splicing programmes that would otherwise
promote epithelial–mesenchymal plasticity.
◀ Figure 7. miR-200–QKI coordinates splicing and expression changes in the actin cytoskeletal network in cancer.A Representative graphs of splice events identified as QKI-responsive in breast TCGA data. The top left graph illustrates the methodology used for de novo identification
of QKI-regulated events where mean PSI differences between the samples with the highest and lowest deciles of QKI expression were calculated.
B Plot of strength of QKI-mediated splicing changes from TCGA breast cancer data versus statistical significance of the change. The most significant alternative splicing
event for each gene is plotted. The top 20 genes identified as having splicing regulated by binding of QKI during EMT (as in Fig 5B) are labelled.
C Heat map showing clustering of QKI-responsive alternatively spliced events across epithelial TCGA cancers. Genes identified as having splicing regulated by binding of
QKI during EMT (as in Fig 5B) are marked with black bars or, where such genes have functions related to actin cytoskeleton dynamics, are marked with red bars and
are named.
D Gene ontology analysis of genes identified as having splicing regulated by binding of QKI during EMT.
E Gene ontology analysis on genes exhibiting QKI-responsive alternative splicing changes in multiple cancers (cluster II in Fig 7C).
F Venn diagram of overlap between genes that exhibit QKI-directed splicing changes during EMT and are directly bound by miR-200a/141 or miR-200b/200c (as
identified by miR-200 Argonaute HITS-CLIP (Bracken et al, 2014)). The genes in the intersection set are named, with those having a function related to actin
cytoskeleton dynamics underlined and those whose splicing is broadly conserved in carcinomas shown in red.
G Quantitation of alterative splicing changes (qPCR) and total transcript levels (from RNA-seq, FPKM) following miR-200c transfection of mesHMLE cells for 3 days.
Western blot of total MPRIP levels in these samples is also shown.
H Actin cytoskeletal pathway adapted from Bracken et al (2014) with miR-200 direct targets highlighted in blue, QKI direct targets in red and QKI-responsive targets in
pink. Major outputs on actin dynamics are indicated.
Source data are available online for this figure.
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We found QKI-5 is also suppressed by a second miRNA, miR-
375, which is known to be enriched in certain epithelial cells and
can maintain epithelial features (Ward et al, 2013; Selth et al,
2017), but also plays prominent roles in regulating pancreatic cell
function and endocrine signalling (Poy et al, 2004, 2009). Interest-
ingly, miR-375 is also subject to transcriptional repression by ZEB1
(Selth et al, 2017). This suggests that ZEB1 acts within a feedback
loop to increase QKI-5 levels and enhance mesenchymal splicing by
coordinately limiting both miR-375 and miR-200 expression. As both
miR-200c and miR-375 act both on the mRNA level and on transla-
tion of QKI-5, this ZEB1/miR-200/miR-375/QKI-5 regulatory loop is
particularly strong, producing the strongly mesenchymal expression
pattern of QKI we observed in the panel of breast cancer cell lines
that we examined, paralleling the mutually exclusive expression of
miR-200c and ZEB1 (Gregory et al, 2008). Since QKI has notable
functions outside of EMT, including regulating neuronal (Larocque
et al, 2005; Zhao et al, 2006; Hayakawa-Yano et al, 2017), smooth
muscle and vascular (Noveroske et al, 2002; Li et al, 2003; van der
Veer et al, 2013; Cochrane et al, 2017) cell function, and alternative
splicing programmes during muscle cell (Hall et al, 2013) and
monocyte (de Bruin et al, 2016a) differentiation, we propose that
the ZEB1/miR-200c/miR-375/QKI-5 pathway may influence splicing
outcomes that impact a broad range of cell differentiation contexts.
Although several studies have indicated QKI is involved in
cancer-associated splicing, its action to date has largely been
inferred from motif analysis or from effects on single target genes,
with the exception of a global analysis in lung cancer cells (Novikov
et al, 2011; Zong et al, 2014; Danan-Gotthold et al, 2015; de Miguel
et al, 2016; Yang et al, 2016). By combining global QKI-5 CLIP-seq
with RNA-seq analysis in an EMT system, we identified 242 skipped
exon events (in 140 genes) directly regulated by QKI-5 (Table EV7),
with direct and indirect alternative splicing targets constituting
approximately one-third of EMT alternative splicing events
(Fig EV4D). Importantly, QKI-5 was both sufficient and necessary to
drive EMT-associated alternative splicing, even in the absence of
EMT inducers. The observation that where QKI promotes exon skip-
ping, it is via binding at or near the skipped 30 splice site is consistent
with a model in which QKI competes with U2 snRNA for the branch
point, since they have the same sequence determinants for binding.
Together, our data demonstrate that dynamic changes in QKI-5
expression that occur during EMT and MET are a major determinant
of mesenchymal splicing programmes. In contrast to QKI-5, ESRP1
and ESRP2 are strongly downregulated during EMT and drive
epithelial splicing programmes when re-introduced into mesenchy-
mal cells (Warzecha et al, 2009; Brown et al, 2011; Shapiro et al,
2011). A recent study indicated ESRP1/2 and QKI could co-regulate
and induce opposing alternative splicing in at least twelve splice
events, including CLSTN1, MPRIP, EXOC1 and DEPDC1 which we
describe here to be QKI-regulated (Yang et al, 2016). Furthermore,
ESRP1 and QKI-5 were respectively the most up- and downregulated
splicing factors in response to miR-200c expression in mesenchymal
cells (Appendix Fig S2), likely owing to loss of ZEB1-mediated tran-
scriptional repression of ESRP1/2 (Horiguchi et al, 2012; Preca et al,
2015) and direct targeting of QKI-5. Collectively, our observations
indicate that the miR-200-ZEB loop coordinates an opposing balance
of QKI-5 and ESRP1 expression to orchestrate widespread EMT-asso-
ciated alternative splicing programmes. However, it is likely that
other splicing factors also implicated in EMT, such as RBFOX2,
MBNL1/2 and RBM47, work cooperatively with QKI-5 and ESRP1 to
fine-tune alternative splicing patterns (Shapiro et al, 2011; Venables
et al, 2013a,b; Braeutigam et al, 2014; Yang et al, 2016; Neumann
et al, 2018).
By comparing exon usage and QKI expression in tumours, we
found that the QKI alternative splicing signature is conserved across
a range of epithelial-derived tumours, indicative of their direct
contributions to cancer progression. QKI-regulated alternative splic-
ing events are enriched with functions involving control of actin
cytoskeletal dynamics, with the splicing of ENAH (MENA) and
NUMB directly linked to several EMT-associated properties (Di
Modugno et al, 2012; Lu et al, 2015). Other genes such as CD44 and
EXOC7 exhibit profound changes in splicing that are required for
actin dynamics and/or EMT, but are regulated by ESRP1 rather than
QKI-5 (Brown et al, 2011; Lu et al, 2013). Here, we show that
modulation of QKI-5 levels exerts pleiotropic effects on mesenchy-
mal cells including changes to cell morphology, migration, invasion,
focal adhesions and tumour growth. Collectively, these QKI-5-regu-
lated phenotypes are consistent with clinical data where QKI-5 is
enriched in breast and prostate cancers with increased invasive and
metastatic potential. Interestingly, several other studies have indi-
cated that QKI can also play tumour suppressive roles (Chen et al,
2012; Zong et al, 2014; Bandopadhayay et al, 2016), and in one
case, QKI-directed alternative splicing of NUMB has been shown to
reduce growth of lung cancer cells in vivo (Zong et al, 2014). Thus,
QKI may play a dual role in cancer progression, limiting the initial
formation of tumours but increasing their subsequent invasiveness
through regulating the splicing of different target genes, such as
through promotion of mesenchymal ENAH splicing. It is also impor-
tant to note that although QKI-5 knockdown produced modest and
inconsistent effects on gene expression (Fig EV4), we cannot rule
out that QKI-5 may also directly or indirectly influence specific
mRNA or miRNAs to regulate different aspects of cancer progres-
sion, as has been reported in other contexts (Chen et al, 2012; Lu
et al, 2014; Yu et al, 2014; Shingu et al, 2017; Zhou et al, 2017).
Similarly, QKI-5 also regulates circRNA formation during HMLE cell
EMT (Conn et al, 2015), and although the functions of these mole-
cules remain poorly understood, they could contribute to epithelial–
mesenchymal plasticity.
In addition to modulating alternative splicing through QKI-5,
miR-200 directly represses expression of many genes involved in
regulating actin cytoskeletal dynamics (Bracken et al, 2014). By
intersection of direct miR-200 and QKI bound transcripts, we
provide evidence that a subset of these genes are co-regulated by
both miR-200c and QKI-5. This finding represents a novel mecha-
nism of coordinate control of both the abundance and alternative
splicing of specific factors, which to our knowledge has not been
reported previously. Of the three genes we assessed, MPRIP and
MYOF have been previously verified as miR-200 targets and directly
influence cell migration and invasion (Li et al, 2012; Bracken et al,
2014; Volakis et al, 2014), but the expression and function of splice
variants of these proteins have not been assessed. More broadly,
miR-200 and QKI-5 regulate the expression and/or alternative splic-
ing of a number of genes which directly interact with each other
and integrate into signalling networks that drive cytoskeletal
changes influencing cell morphology, migration and invasion
(Fig 7H). Several of these alternatively spliced products including
ENAH (MENA), PARD3 and NIN display altered phosphorylation,
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protein–protein interactions and cell localisation, respectively (Gao
et al, 2002; Balsamo et al, 2016; Zhang et al, 2016). A future chal-
lenge will be assessment of the functions of these isoforms and their
impact on epithelial plasticity.
Materials and Methods
Cell culture, transfection and production of stable cell lines
Human breast cancer cell lines were cultured as described previ-
ously (Gregory et al, 2008). HMLE cells (Mani et al, 2008) were
cultured in HuMEC Ready Media (ThermoFisher) and induced to
undergo EMT by transferring to DMEM:F12 media (1:1) supple-
mented with 10 lg/ml insulin, 20 ng/ml EGF, 0.5 lg/ml hydrocorti-
sone and 5% foetal calf serum (FCS) and treating with 2.5 ng/ml of
TGF-b1 (R&D) for at least 14 days. MesHMLE cells, which are
derived from HMLE from prolonged treatment with TGF-b1 (Mani
et al, 2008), were maintained in EMT-inducing media without addi-
tional TGF-b1. MCF-10A cells were cultured in DMEM:F12 media
(1:1) supplemented with 10 lg/ml insulin, 20 ng/ml EGF, 0.5 lg/
ml hydrocortisone, 100 ng/ml cholera toxin and 5% horse serum
and induced to undergo EMT by adding 1.0 ng/ml of TGF-b1 for
14 days. MDCK cells were cultured in DMEM + 10% FCS and
induced to undergo EMT by addition of 1.0 ng/ml of TGF-b1 for
12 days. SH-EP cells were maintained in DMEM + 10% FCS. LNCaP
cells and derivative inducible ZEB1 (provided by Brett Hollier) and
QKI-5 cells were maintained in RPMI + 10% FCS. For doxycycline
induction experiments, 1 lg/ml was added to the media for 6 days
followed by its removal for up to 10 days.
For transfection experiments, cells were transfected with 20 nM
miRNA precursors (mirVana miRNA mimics; Ambion), 20 nM
siRNA (ON-TARGETplus siRNA; Dharmacon) or 20–100 nM anti-
miRNA (miRCURY LNA Power microRNA inhibitor; Exiqon) using
Lipofectamine RNAiMAX (ThermoFisher) for 72 h unless otherwise
specified prior to downstream functional assays. Details of miRNA
precursors, anti-miRs and siRNA are provided in Table EV8. For the
HMLE EMT timecourse, siRNAs were re-transfected upon passaging
at each indicated time point.
Cell lines with stable overexpression or knockdown of QKI-5
were generated using vectors and methodology as previously
described (Conn et al, 2015) and are listed in Table EV8. To gener-
ate cell lines with inducible QKI-5 expression, pENTR2B-QKI-5 were
recombined with pInducer20 (Meerbrey et al, 2011) using LR
Clonase to produce pInducer20-QKI-5. Lentivirus was produced
from pInducer20-ZEB1 and pInducer20-QKI-5 following Lipofec-
tamine 2000 (ThermoFisher)-mediated co-transfection of HEK293T
cells with each vector along with pCMV-VSVG and pCMV-dR8.2. A
1:4 dilution of viral supernatant was used to transduce LNCaP and
MCF-7 cell lines, after which pools of cells were selected for using
1.0 mg/ml of G418, respectively.
RNA extraction and PCR
RNA was extracted using TRIzol (ThermoFisher) as per the
manufacturer’s instructions. For mRNA PCR, reverse transcription
was carried out using random hexamers on 1.0 lg of total RNA
using the QuantiTect RT kit (Qiagen) which was diluted 1:10 or
1:20 prior to quantitative PCR (qPCR) or semi-quantitative PCR
(sqPCR). qPCR was performed in triplicate using the QuantiTect
SYBR Green PCR kit (Qiagen) on a Rotor-Gene 6000 series PCR
machine (Qiagen). Analysis was performed using comparative
quantitation feature of the Rotor-Gene software with data
normalised to GAPDH expression. sqPCR for alternative splicing
analysis was performed using Standard Taq polymerase (NEB) or
Phusion DNA Polymerase (ThermoFisher). MicroRNA qPCR was
performed using 5.0 ng of RNA using TaqMan microRNA assay
kits (Applied Biosystems) according to the manufacturer’s
instructions, with data normalised to U6 small nuclear RNA. For
mapping of the QKI 30UTRs, cDNA was synthesised using the
specific reverse transcription primers (locations in Fig EV2) and
sqPCR performed using Standard Taq polymerase (NEB) with
QKI isoform-specific primer sets. All primer sequences are shown
in Table EV8.
Immunoblotting and quantitation
Protein extracts were prepared from transfected cells with Triton X-
100 lysis buffer (50 mM HEPES, pH 7.5, 150 mM sodium chloride,
10 mM sodium pyrophosphate, 5 mM EDTA, 50 mM sodium fluo-
ride, 1% Triton X-100 and protease inhibitor cocktail) and 20 lg
fractionated on a SDS polyacrylamide gel. After transfer onto a
nitrocellulose membrane and blocking in 5% skim milk for 1 h at
room temperature, probing was carried in 5% skim milk overnight
at 4°C using antibodies and dilutions as described in Table EV8.
Membranes were exposed using the ECL method on a ChemiDoc
imaging system (Bio-Rad). Quantitation relative to an a-tubulin
loading control was carried out using FIJI software (Schindelin et al,
2012).
Immunofluorescence and quantitation
Cells were transfected with microRNA precursors or siRNAs as
described above, plated onto fibronectin-coated chamber slides
(Nunc) and immunostained after 72 h. Cells were fixed in 4%
paraformaldehyde, permeabilised in 0.1% Triton X-100 and
probed with a 1:200 dilution of anti-E-cadherin, paxillin or b-
catenin antibodies for 1 h at room temperature. Primary anti-
bodies were detected with a 1:200 dilution of Alexa 488- and
Alexa 594-conjugated secondary antibodies for 1 h at room
temperature. For F-actin staining, fixed and permeabilised cells
were incubated with 1:200 dilution of rhodamine phalloidin
(Molecular Probes) for 30 min at room temperature. Sections
were mounted in ProLong Gold Antifade Reagent containing
DAPI (Molecular Probes). Confocal images were acquired under
a confocal microscope (LSM 700; Zeiss). Antibodies are detailed
in Table EV8.
For analysis of cell shape (length:width ratio) or cell area of F-
actin-stained cells, measurements were made using the line tool on
FIJI software (Schindelin et al, 2012). Cell length was defined by the
longest distance between any two points of the cell, and cell width
was measured as the longest line perpendicular to the cell-length
line. Cell area was measured as the area encompassed following
demarcation of the cell circumference. Measurements were
conducted in a minimum of sixty F-actin-stained cells per treatment.
For analysis of focal adhesion number and length, focal adhesions
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were identified in whole paxillin-stained cells and measured with
the arbitrary line tool on the AnalySIS LS software (Olympus). A
minimum of 500 focal adhesions were counted on at least 20 cells
per treatment.
Luciferase reporter assays
An ~2.3-kb segment of the QKI-5 30UTR was amplified from MDA-
MB-231 gDNA and cloned into XhoI and NotI sites of psiCheck2
(Promega). Proximal (853 bp) and distal (443 bp) regions of the
QKI-5 30UTR containing miR-375 and miR-200c sites were amplified
from psiCheck2-QKI-5 30UTR and re-cloned into psiCheck2. Muta-
tions in the miR-375 and miR-200c sites were generated by cloning
in equivalent synthesised GeneArt gene fragments (ThermoFisher)
to the proximal and distal regions. Transfections were carried out
by co-transfecting 5 nM miRNA (mirVana miRNA mimics; Ambion)
with psiCheck reporters in MDA-MB-231 cells in triplicate for 48 h.
Reporter assays were performed three times using the Dual Luci-
ferase reporter assay system (Promega) with one representative
experiment shown. Primer sequences for cloning are shown in
Table EV8.
Migration and invasion assays
Migration or invasion assays were performed by plating cells in
Transwells (Corning, 6.5 mm, 8.0 mm pore size) or BioCoat
Matrigel chambers (BD Biosciences, 6.5 mm, 8.0 mm pore size),
respectively, in serum-free medium with 0.01% bovine serum albu-
min. Chemotactic migration/invasion was induced be adding 10%
FCS to the lower chamber. For MDA-MB-231 and mesHMLE cells,
2 × 105 or 8 × 104 cells were utilised in 4-h migration or 24-h inva-
sion assays, respectively. For SH-EP cells, 8 × 104 cells were utilised
in 24-h invasion experiments. Following experimental endpoint,
membranes were fixed with 10% buffered formalin and cells stained
with DAPI. Six fields of view for each membrane were counted
using FIJI software (Schindelin et al, 2012). All experiments
included at least 3–4 replicates and were performed multiple times
with data pooled and shown as mean  SEM.
For non-directional cell migration, transfected cells were plated
at low density and images were collected on the IncuCyte Zoom
(Essen Bioscience) every hour for 24 h. Cell tracking was performed
manually with 25 cells per group using the manual tracking and
chemotaxis tools on FIJI software (Schindelin et al, 2012).
Colony formation assays
Soft agar colony formation assays were set up in 6-well plates using
a base layer of 1.5 ml of 0.5% low-melting-point agarose (Sigma
A9045) in normal growth media, with a top layer of 2.0 ml of 0.33%
low-melting-point agarose/growth media incorporating 2 × 104
mesHMLE cells. Colonies were allowed to form for 14 days and were
visualised by phase imaging. Colonies were enumerated using the
particle counting module on FIJI software (Schindelin et al, 2012).
Mice and tumour growth assays
NOD/SCID mice were housed in the SA Pathology Animal Care
Facility, and experiments were conducted under the institutional
animal ethics guidelines. Mice were anaesthetised before injections
of 1 × 106 MDA-MB-231 LM2 cells (Minn et al, 2005) in 50 ml of
50% Matrigel (BD Biosciences) into the fourth mammary gland. Ten
mice per group were used for each cell line. Tumour volume was
measured using electronic callipers every 3–5 days over a 33-day
period.
Clinical public data sets and merging with experimental
data sets
To assess correlations between miR-200c or miR-375 and gene
expression in clinical data sets, we performed linear regression anal-
ysis using R, generating Pearson correlation coefficients and
q-values for all annotated genes. Clinical data sets used were Enerly
breast cancer (GSE19783, n = 101) (Enerly et al, 2011), Taylor pros-
tate cancer (GSE21032, n = 111) (Taylor et al, 2010), The Cancer
Genome Atlas (TCGA) breast and prostate cancer (n = 834 and 466,
respectively) and the NCI-60 cancer cell line panel (Liu et al, 2010).
Experimental data sets were merged with clinical data to generate a
ranked list of most consistent miR-200c targets including: microar-
ray data of untreated or MDCK cells treated with TGF-b for 12 days
(MDCK EMT, GeneChip Canine 2.0 arrays (Affymetrix), this study),
microarray data of untreated or HMLE cells treated with TGF-b for
15 days (HMLE EMT, GeneChip Human Gene 1.0 ST Array (Affyme-
trix), this study), microarray data of MDA-MB-231 transfected with
negative control or miR-200b for 3 days (MB-231 + miR-200, Gene-
Chip Human Gene 1.0 ST Array (Affymetrix), this study), and
miR-200b targets identified by Ago-HITS-CLIP of miR-200b in MDA-
MB-231 cells (miR-200 HITS-CLIP (Bracken et al, 2014)). Differen-
tial expression in microarray data sets was assessed using the
Robust Multichip Average method in the Partek Genomics Suite
(v6.5). Genes upregulated by more than 1.5-fold (MDCK EMT,
n = 1,467) and 1.3-fold (HMLE EMT, n = 2,690) and downregulated
by 1.5-fold (MB-231 + miR-200b, n = 1,064) which possessed
conserved putative miR-200c target sites (TargetScan 6.2 (Garcia
et al, 2011), n = 1,057) were included in the miR-200c target identi-
fication pipeline. Pearson correlations between miR-375 and QKI in
the above clinical data sets, and relative expression of QKI in
tumour subsets and significance calculations were assessed using
GraphPad Prism software. The relative expression of QKI in prostate
primary versus metastasis samples was assessed in the Oncomine
platform (ThermoFisher). The relative expression of QKI in tumour
versus normal samples in the panTCGA cancer panel was obtained
from Firebrowse Gene Expression Viewer (http://firebrowse.org).
Association recurrence of miR-200c with the 20 highest ranking
miR-200c targets in the panTCGA, as well as QKI with all miRNAs,
was assessed using the CancerMiner database (Jacobsen et al,
2013). Gene expression profiling of MDA-MB-231 cells transfected
with negative control or QKI-5 siRNAs for 6 days was performed on
GeneChip Human Gene 2.0 ST Array (Affymetrix). Microarray data
for all data sets are provided in Table EV9.
RNA-seq library preparation, gene expression and alternative
splicing analysis
Poly(A) RNA was isolated using NEBNext Poly(A) mRNA
Magnetic Isolation Module columns according to the manufac-
turer’s instructions. The poly(A) fraction was size-fractionated and
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concentrated using 3.53 AMPure RNAClean XP sample preparation
(New England Biolabs) and eluted with water. Stranded RNA
libraries were made using the NEBNext Ultra Directional RNA
Library Prep Kit for Illumina (New England Biolabs), and 100-bp
paired-end sequencing was performed on multiplexed libraries (be-
tween 2 and 4 indexes) on an Illumina HiSeq 2500 at the ACRF
Cancer Genomics Facility. Three biological replicates were
prepared for HMLE or MesHMLE and two replicates for knock-
down of QKI or ectopic expression of miR-200c in MesHMLE cells.
Details of read processing, mapping and statistics are provided in
Table EV1 and described in detail in Appendix Supplementary
Methods. Gene expression analysis was performed using the cuffd-
iff command from cufflinks v2.1.1 with genes having ≥ 2-fold
change in expression with a q-value of ≤ 0.05 considered signifi-
cant. For alternative splicing analysis, to ensure robust results we
utilised three diverse algorithms: rMATS (Shen et al, 2014),
DEXSeq (Anders et al, 2012) and cuffdiff. A ranking system based
on the integration of results from the three programs was used to
shortlist genes for validation and is described in details in
Appendix Supplementary Methods and presented in Table EV6.
Figures were prepared from rMATS results, with genes possessing
a percentage spliced in (PSI) difference of ≥ 5% and a false
discovery rate (FDR) of ≤ 0.05 considered significant unless other-
wise specified. Summary outputs of gene expression and alterna-
tive splicing analysis are provided in Tables EV2 and EV4. Further
details on analysis of RNA-seq data are provided in Appendix Sup-
plementary Methods.
QKI-5-CLIP and sequencing
The QKI-CLIP method was adapted from published methods (Jensen
& Darnell, 2008), incorporating modifications from eCLIP (Van
Nostrand et al, 2016) and iCLIP (Sutandy et al, 2016)
(Appendix Supplementary Methods; Appendix Fig S1). A detailed
protocol is included in Appendix Supplementary Methods. In short,
mesHMLE cells were crosslinked and QKI-5 bound RNA immuno-
precipitated with a QKI-5-specific antibody (Bethyl, A300-183A).
Libraries were prepared including a size-matched input control as
per eCLIP (Van Nostrand et al, 2016). Peaks of reads signifying QKI-
5 binding were identified using MACS2 (Zhang et al, 2008), and
comparison of QKI-5 CLIP peaks and skipped exon events following
QKI-5 knockdown or during EMT was performed using rMAPS (Park
et al, 2016). Further details of QKI-CLIP analysis are provided in
Appendix Supplementary Methods.
Gene ontology analysis
Analysis of gene ontology was performed using the Functional
Classification Tool of Database for Annotation, Visualization and
Integrated Discovery (DAVID) (Huang da et al, 2009a,b). The most
significant category from the top five most significant default anno-
tation clusters is displayed for each analysis.
TCGA splicing data analysis
To analyse the relationship between differential alternative splicing
and QKI expression, The Cancer Genome Atlas (TCGA) gene expres-
sion and splice junction read count data were obtained from the
Broad GDAC Firehose website (http://gdac.broadinstitute.org/).
Full details of the methods used are provided in Appendix Supple-
mentary Methods. Briefly, a metric similar to PSI was calculated for
every represented junction (in both orientations). Mean PSIs were
calculated and compared for the 10% of samples with the highest
and lowest expression of QKI. This was performed for seven epithe-
lial-derived cancers (breast BRCA, prostate PRAD, bladder BLCA,
pan-kidney KIPAN, lung adenocarcinoma LUAD, lung squamous
cell carcinoma LUSC, stomach and esophageal STES), each of which
comprised a minimum of 450 samples. The consistency of QKI-
correlated changes in splicing was analysed by unsupervised clus-
tering, where the genes represented were constitutively expressed in
all cancers and possess large QKI-correlated changes in splicing (a
mean difference in PSI between QKI-high and QKI-low samples of at
least 35% in at least one cancer). Further details are provided in
Appendix Supplementary Methods.
Statistics and reproducibility
Statistical analysis was carried out using GraphPad Prism software
and data are represented as the mean  SD unless otherwise indi-
cated. For migration, invasion and cell tracking assays, results are
shown as shown as mean  SEM with significance measured by
two-tailed unpaired t-tests. For measurement of cell shape, area and
focal adhesion length, significance was measured by Mann–Whitney
test. For comparison of cancer subtypes, significance was measured
by two-tailed unpaired t-tests. Significance is expressed as
*P < 0.05, **P < 0.01 and ***P < 0.001.
Data availability
The RNA sequencing data from this publication have been deposited
to the European Nucleotide Archive database (http://www.ebi.ac.
uk/ena/data/view/PRJEB25042) with the study accession number
PRJEB25042. The QKI-5 HITS-CLIP data from this publication have
been deposited in NCBI’s Gene Expression Omnibus (https://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE111188) and are
accessible through GEO Series accession number GSE111188.
Expanded View for this article is available online.
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